Claus Bogh Juhl

Head of endocrinology dept. · Esbjerg Hospital - University Hospital of Southern Denmark · Hospital of South West Jutland, 6700 Esbjerg , Denmark

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Claus Bogh Juhl as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:59 UTC. Open this list on ClinicalTrials.gov

Ph2/Ph3
NCT06619015 · Tailoring Obesity Treatment Trial
Esbjerg Hospital - University Hospital of Southern Denmark · withdrawn · Obesity, Appetite Regulation, PreDiabetes · principal investigator
Ph2
NCT06421597 · Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease
Odense University Hospital · completed · Osteoporosis Secondary · principal investigator
N/A
NCT05708417 · A Weight-Neutral Approach for a Healthier Lifestyle Among Obesity - A Lifestyle Intervention Anchored in SDOI
Esbjerg Hospital - University Hospital of Southern Denmark · unknown · Health Related Quality of Life and Weight Condition · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:59 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Diabetes · 2004
364 citations
RCR 8.8
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Diabetes · 2002
225 citations
RCR 5.3
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
Diabetes · 2004
217 citations
RCR 5.4
Acute pain induces insulin resistance in humans.
Anesthesiology · 2001
115 citations
RCR 3.7
Fear avoidance beliefs as a predictor for long-term sick leave, disability and pain in patients with chronic low back pain.
BMC Musculoskelet Disord · 2018
73 citations
RCR 5.4
Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes.
Diabetes · 2000
56 citations
RCR 1.2
Supervised Physical Training Improves Weight Loss After Roux-en-Y Gastric Bypass Surgery: A Randomized Controlled Trial.
Obesity (Silver Spring) · 2018
56 citations
RCR 3.2
Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans.
Diabetologia · 2002
53 citations
RCR 1.5
Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease.
Int J Chron Obstruct Pulmon Dis · 2022
51 citations
RCR 4.5
Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.
J Clin Endocrinol Metab · 2003
49 citations
RCR 1.1